WHO Recommendation AstraZeneca/SKBio - COVID-19 Vaccine (ChAdOx1-S [recombinant])
Product Overview |
|||
Vaccine type: | COVID-19 Vaccine (ChAdOx1-S ([recombinant]) | ||
Commercial name: | Vaxzevria | ||
Manufacturer: | AstraZeneca/SK Bioscience Co. Ltd | ||
Country: | Republic of Korea | ||
URL: | https://www.astrazeneca.com https://www.skbioscience.co.kr/kr/main |
||
Responsible NRA: | Ministry of Food and Drug Safety | ||
Country: | Republic of Korea | ||
URL: | |||
WHO Recommendation |
|||
Effective date: | 15 February 2021 | ||
Product Description |
|||
Pharmaceutical form: | Solution for injection | ||
Presentation: | Vial | ||
Number of doses: | 10 doses | ||
Diluent: | Not applicable | ||
Route of administration | Intramuscular | ||
Shelf-life: | 6 months | at storage temperature: | 2°C to 8°C |
Vaccine vial monitor: | None | ||
Secondary packaging: | Carton holds 10 vaccine vials (100 doses) Dimensions: 13.2 x 5.7 x 5.0 cm |
||
Tertiary packaging: | 24 secondary packaged cartons containing 10 vials per carton (240 vials /2400 doses): Dimensions: 24.8 x 28.8 x 18.0 cm |
||
Cold chain volume: | 3.76 | cm3 (in secondary packaging) | |
Preservative: | Not applicable | with concentration: | Not applicable |
Handling of opened multidose-vials: | WHO recommends that opened vials of this vaccine should be discarded 6 hours after opening or at the end of the immunization session, whichever comes first. |